TABLE 3.

Results of hypothesis testing in the model development procedure.

Model no.	Model description	OFV	ΔOFV	P-value
Forward inclusion 1
1	Base model	2595.456
2	Add WT on CL/F in Model 1	2435.963	−159.493	<0.001
3	Add AGE on CL/F in Model 1	2417.706	−177.750	<0.001
4	Add TDD on CL/F in Model 1	2595.416	−0.040	NS
5	Add SEX on CL/F in Model 1	2595.347	−0.109	NS
6	Add LEV on CL/F in Model 1	2595.468	0.012	NS
7	Add OXC on CL/F in Model 1	2593.070	−2.386	NS
8	Add TPM on CL/F in Model 1	2593.728	−1.728	NS
9	Add CNZ on CL/F in Model 1	2591.536	−3.920	<0.05
10	Add PB on CL/F in Model 1	2595.455	−0.001	NS
11	Add MDZL on CL/F in Model 1	2591.975	−3.481	NS
12	Add ABCB1 rs3789243 on CL/F in Model 1	2586.368	−9.088	<0.01
13	Add ABCB1 rs1128503 on CL/F in Model 1	2589.456	−6.000	<0.05
14	Add ABCC2 rs2273697 on CL/F in Model 1	2594.987	−0.469	NS
15	Add CYP1A1 rs2606345 on CL/F in Model 1	2594.706	−0.750	NS
16	Add LEPR rs1137101 on CL/F in Model 1	2592.391	−3.065	NS
17	Add MTHFR rs1801131 on CL/F in Model 1	2595.074	−0.382	NS
18	Add SCN1A rs6730344 on CL/F in Model 1	2593.524	−1.932	NS
19	Add SCN1A rs10167228 on CL/F in Model 1	2594.216	−1.240	NS
20	Add SCN1A rs3812718 on CL/F in Model 1	2587.310	−8.146	<0.01
21	Add SCN1A rs2298771 on CL/F in Model 1	2593.886	−1.570	NS
22	Add SCN2A rs2304016 on CL/F in Model 1	2592.423	−3.033	NS
23	Add SCN2A rs17183814 on CL/F in Model 1	2594.704	−0.752	NS
Forward inclusion 2
24	Add CNZ on CL/F in Model 3	2413.940	−3.766	NS
25	Add ABCB1 rs3789243 on CL/F in Model 3	2408.473	−9.233	<0.01
26	Add ABCB1 rs1128503 on CL/F in Model 3	2415.917	−1.789	NS
27	Add SCN1A rs3812718 on CL/F in Model 3	2415.719	−1.987	NS
Backward elimination
28	Remove AGE on CL/F from Model 25	2586.368	177.895	<0.001
29	Remove ABCB1 rs3789243 on CL/F from Model 25	2417.706	9.233	<0.01

WT, weight; TDD, VPA total daily dose; LEV, levetiracetam; OXC, oxcarbazepine; TPM, topiramate; CNZ, clonazepam; PB, phenobarbital; MDZL, midazolam.